Search company, investor...

Lydus Medical

Founded Year



Seed VC - II | Alive

Total Raised


Last Raised

$2.7M | 2 yrs ago

About Lydus Medical

Lydus Medical offers Vesseal, an automated microvascular suturing device delivering thread-only, standardized omni-vessel anastomoses to enable simple, fast, easy, safe, and effective procedures.

Headquarters Location

13 Zarchin St. POB 2219

Ra'anana, 4366241,



Compete with Lydus Medical?

Ensure that your company and products are accurately represented on our platform.

Lydus Medical's Products & Differentiators


    Anastomotic assist device for end-to-end anastomoses ranging 2-4mm

Expert Collections containing Lydus Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Lydus Medical is included in 2 Expert Collections, including Medical Devices.


Medical Devices

8,560 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,901 items

Lydus Medical Patents

Lydus Medical has filed 1 patent.

The 3 most popular patent topics include:

  • Digestive system surgery
  • Congenital heart defects
  • Digestive system
patents chart

Application Date

Grant Date


Related Topics




Digestive system surgery, Implants (medicine), Muscles of the upper limb, Lithics, Upper limb anatomy


Application Date


Grant Date



Related Topics

Digestive system surgery, Implants (medicine), Muscles of the upper limb, Lithics, Upper limb anatomy



Latest Lydus Medical News

Israel High Tech Scene Week In Review June 6 – 12

Jun 12, 2021

Lydus Medical is an Israeli medtech startup developing a novel product line for automating the creation of small blood vessel anastomoses. The company’s Vesseal is an automated microvascular suturing device that delivers a standardized, thread-only, omni-vessel anastomosis to enable simple, fast, safe, and effective procedures. The company that operates the Notal Vision Diagnostic Clinic. Notal Vision is an Israeli medtech diagnostic services company that operates the Notal Vision Diagnostic Clinic, a medical provider with a proven platform for engaging patients and AI-enabled analyses of high-volume personalized health data that extends disease management from the clinic to the home to improve vision outcomes, reduce treatment burden, and improve health economics. Stoke just raised $15.5 million. Israeli startup Stoke Talent is a freelance management system (FMS). The company declares that its solution makes it easy for companies to work with independent contractors, reduces the hassle of hiring, onboarding, tracking and managing invoices, while ensuring full legal and tax compliance. IPOs and Unicorns The company brought in $200 million. Exabeam, an Israeli security analytics and automation company, hit unicorn status with a $2.4 billion valuation. The coveted status of unicorn came when Exbeam raised $200 million in a Series F growth round led by the Owl Rock division of Blue Owl Capital and supported by existing investors Acrew Capital, Lightspeed Venture Partners and Norwest Venture Partners. Verbit just recently bought out another startup. Verbit, an Israeli developer of an AI-powered transcription and captioning platform, has now hit the coveted unicorn status. Verbit broke the $1 billion valuation mark with a $157 million Series D round of funding. Other Business Stories Google is also under investigation in America. Google has been fined 220 million euros ($268 million) by France’s antitrust watchdog for what the organization describes as abuse of Google’s position in online advertising. There is, of course, nothing new to the allegation that Google engages in anti-competitive – some would even say monopolistic – practices when it comes to how the company handles its advertising business, uses data collected on billions of users every day and how the company takes advantage of all the devices which run on its free Android operating system. The deal is not yet final. Bill Ackman’s Pershing Square Tontine Holdings (PSTH) confirmed that it is in discussions with Vivendi S.E. (“Vivendi”) to acquire 10% of the outstanding Ordinary Shares of Universal Music Group B.V. (“UMG”) for approximately $4 billion. Such an acquisition would leave Universal Music Group with a valuation of $42.4 billion, said Pershing Square in a statement.

Lydus Medical Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Lydus Medical Rank

Lydus Medical Frequently Asked Questions (FAQ)

  • When was Lydus Medical founded?

    Lydus Medical was founded in 2017.

  • Where is Lydus Medical's headquarters?

    Lydus Medical's headquarters is located at 13 Zarchin St., Ra'anana.

  • What is Lydus Medical's latest funding round?

    Lydus Medical's latest funding round is Seed VC - II.

  • How much did Lydus Medical raise?

    Lydus Medical raised a total of $2.7M.

  • Who are the investors of Lydus Medical?

    Investors of Lydus Medical include Sanara Ventures, GlenRock Israel and Mor Research.

  • Who are Lydus Medical's competitors?

    Competitors of Lydus Medical include Sutures.

  • What products does Lydus Medical offer?

    Lydus Medical's products include Vesseal.

Compare Lydus Medical to Competitors

Sutures Logo

Sutures, developed by the team, is a mobile application and digital toolkit that allows surgeons to explain surgical procedures via a highly interactive anatomy workspace.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.